What is MedLumics?
Founded in Madrid in 2011, MedLumics is a specialized medical technology enterprise dedicated to the design and development of advanced diagnostic and therapeutic systems. The company's flagship innovation, AblaView, represents a significant leap forward in cardiac care, providing clinicians with real-time, optically guided feedback during radio-frequency ablation procedures. By enabling the direct assessment of catheter positioning and the continuity of ablation lesions, MedLumics addresses the fundamental challenges of transmurality in the treatment of Atrial Fibrillation. The company operates at the intersection of optics, software engineering, and cardiology, positioning itself as a high-growth entity within the global medtech landscape.
How much funding has MedLumics raised?
MedLumics has raised a total of $63.3M across 3 funding rounds:
Series A
$4.7M
Series B
$36.9M
Other Financing Round
$21.7M
Series A (2011): $4.7M with participation from Ysios Capital Partners and Caixa Capital Risc
Series B (2017): $36.9M led by Ysios Capital Partners, Innogest Capital, Caixa Capital Risc, Edmond de Rothschild Investment, and Seroba Life Sciences
Other Financing Round (2021): $21.7M supported by CDTI Innvierte Economía, Kurma Partners, Asabys Partners Company, and VI Partners Swiss Innovation
Key Investors in MedLumics
Ysios Capital Partners
Ysios Capital is a leading life sciences venture capital firm that invests in highly innovative biotechnology companies worldwide, providing resources to ventures focused on developing novel therapies for high unmet medical needs.
Caixa Capital Risc
CriteriaCaixa is a venture capital firm focused on investing in innovative startups at early stages, particularly in technology, biotechnology, and the industrial sector.
Seroba Life Sciences
Seroba is a European life sciences venture capital firm, focused on investing in winning innovations in biotech and medtech, partnering with entrepreneurs to build businesses around extraordinary science.
What's next for MedLumics?
With the recent influx of $21.7M, MedLumics is strategically positioned to accelerate its clinical development programs and expand its commercial footprint. The focus remains on validating the long-term efficacy of the AblaView system across diverse patient populations and securing regulatory milestones in key international markets. As the company transitions from a development-focused entity to a commercial-stage leader, the integration of its technology into standard electrophysiology workflows will be the primary driver of value creation. Future strategic initiatives will likely involve scaling manufacturing capabilities and deepening partnerships with major healthcare institutions to ensure the widespread adoption of its optically guided ablation solutions.
See full MedLumics company page
